Cancer Chemotherapy and Pharmacology

, Volume 79, Issue 3, pp 559–568 | Cite as

Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies

  • Peter N. Morcos
  • Katrijn Bogman
  • Stanislas Hubeaux
  • Carolina Sturm-Pellanda
  • Thorsten Ruf
  • Walter Bordogna
  • Sophie Golding
  • Ali Zeaiter
  • Markus Abt
  • Bogdana Balas
Original Article



Alectinib, a central nervous system (CNS)-active ALK inhibitor, has demonstrated efficacy and safety in ALK+ non-small-cell lung cancer that has progressed following crizotinib treatment. Other ALK inhibitors have shown concentration-dependent QTc prolongation and treatment-related bradycardia. Therefore, this analysis evaluated alectinib safety in terms of electrophysiologic parameters.


Intensive triplicate centrally read electrocardiogram (ECG) and matched pharmacokinetic data were collected across two alectinib single-arm trials. Analysis of QTcF included central tendency analysis [mean changes from baseline with one-sided upper 95% confidence intervals (CIs)], categorical analyses, and relationship between change in QTcF and alectinib plasma concentrations. Alectinib effects on other ECG parameters (heart rate, PR interval and QRS duration) were also evaluated.


Alectinib did not cause a clinically relevant change in QTcF. The maximum mean QTcF change from baseline was 5.3 ms observed pre-dose at week 2. The upper one-sided 95% CI was <10 ms at all time points. There was no relevant relationship between change in QTcF and alectinib plasma concentrations. Alectinib treatment resulted in a generally asymptomatic exposure-dependent decrease in mean heart rate of ~11 to 13 beats per minute at week 2. No clinically relevant effects were seen on other ECG parameters. Approximately 5% of patients reported cardiac adverse events of bradycardia or sinus bradycardia; however, these were all grade 1–2.


Alectinib does not prolong the QTc interval or cause changes in cardiac function to a clinically relevant extent, with the exception of a decrease in heart rate which was generally asymptomatic.


Alectinib ALK inhibitor NSCLC Cardiac safety ECG data 



Third-party medical writing assistance, under the direction of the authors, was provided by Joanna Musgrove, MRes of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd.

Compliance with ethical standards

Conflict of interest

All authors are employees of F. Hoffmann-La Roche Ltd. and have stock in F. Hoffmann-La Roche Ltd.

Supplementary material

280_2017_3253_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 16 KB)


  1. 1.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F (2014) ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 40:300–306CrossRefPubMedGoogle Scholar
  2. 2.
    Shaw AT, Solomon B (2011) Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 17:2081–2086CrossRefPubMedGoogle Scholar
  3. 3.
    Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE (1014) Investigators (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177CrossRefGoogle Scholar
  4. 4.
    Peters S (2016) Emerging options after progression during crizotinib therapy. J Clin Oncol 34:643–645CrossRefPubMedGoogle Scholar
  5. 5.
    Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH, study investigators (2016) Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234–242CrossRefPubMedGoogle Scholar
  6. 6.
    Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661–668CrossRefPubMedGoogle Scholar
  7. 7.
    International Conference on Harmonization (2005) Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugsGoogle Scholar
  8. 8.
    Van Noord C, Eijgelsheim M, Stricker BHC (2010) Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 70:16–23CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    US Food and Drug Administration (2016) Clinical pharmacology and biopharmaceutics review(s) of alectinib. Accessed 6 July 2016
  10. 10.
    Hsu JC, Carnac R, Henschel V, Bogman K, Martin-Facklam M, Guerini E, Balas B, Hassan Zeaiter A, Phipps A, Morcos PN, Frey N (2016) Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population. J Clin Oncol 34(Suppl; abstr):e20598Google Scholar
  11. 11.
    Fridericia LS (2003) The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol 8:343–351CrossRefPubMedGoogle Scholar
  12. 12.
    Heinig K, Miya K, Kamei T, Guerini E, Fraier D, Yu L, Bansal S, Morcos PN (2016) Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment. Bioanalysis 8:1465–1479CrossRefPubMedGoogle Scholar
  13. 13.
    Morcos PN, Cleary Y, Guerini E, Dall G, Bogman K, De Petris L, Viteri S, Bordogna W, Yu L, Martin-Facklam M, Phipps A (2016) Clinical drug–drug interactions (DDIs) through cytochrome P450 3 A (CYP3A) for alectinib, a highly selective ALK inhibitor. Clin Pharmacol Ther 99(abstr PI-119):S62Google Scholar
  14. 14.
    Gadgeel S, Gandhi L, Riely G, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–1128CrossRefPubMedGoogle Scholar
  15. 15.
    Srinivasamaharaj S, Salame B, Rios-Perez J, Kloecker G, Perez CA (2016) The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer. Expert Rev Anticancer Ther 16:1227–1233CrossRefGoogle Scholar
  16. 16.
    US Food and Drug Administration (2016) Xalkori prescribing information. Accessed 26 July 2016
  17. 17.
    US Food and Drug Administration (2015) Zykadia prescribing information. Accessed 26 July 2016
  18. 18.
    Ou SH, Tong WP, Azada M, Siwak-Tapp C, Dy J, Stiber JA (2013) Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 119:1969–1975CrossRefPubMedGoogle Scholar
  19. 19.
    Ou SH, Azada M, Dy J, Stiber JA (2011) Asymptomatic profound sinus bradycardia (heart rate 45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol 6:2135–2137CrossRefPubMedGoogle Scholar
  20. 20.
    US Food and Drug Administration (2014) Clinical/statistical review of ceritinib. Accessed 26 Aug 2016

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Peter N. Morcos
    • 1
  • Katrijn Bogman
    • 2
  • Stanislas Hubeaux
    • 2
  • Carolina Sturm-Pellanda
    • 2
  • Thorsten Ruf
    • 2
  • Walter Bordogna
    • 2
  • Sophie Golding
    • 2
  • Ali Zeaiter
    • 2
  • Markus Abt
    • 2
  • Bogdana Balas
    • 2
  1. 1.F. Hoffmann-La Roche LtdInnovation CenterNew YorkUSA
  2. 2.F. Hoffmann-La Roche LtdBaselSwitzerland

Personalised recommendations